Enanta Pharmaceuticals
ENTA
150 hedge funds and large institutions have $957M invested in Enanta Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 54 increasing their positions, 57 reducing their positions, and 15 closing their positions.
18% more capital invested
Capital invested by funds: $811M → $957M (+$146M)
0.41% more ownership
Funds ownership: 95.93% → 96.34% (+0.41%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 15
1% less funds holding
Funds holding: 151 → 150 (-1)
5% less repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 57
61% less call options, than puts
Call options by funds: $2.08M | Put options by funds: $5.39M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
+$20.3M |
| 2 |
BlackRock
New York
|
+$16.1M |
| 3 |
AC
Armistice Capital
New York
|
+$14.6M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$11M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.89M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$11.9M |
| 2 |
First Manhattan
New York
|
-$10M |
| 3 |
Millennium Management
New York
|
-$7.63M |
| 4 |
Man Group
London,
United Kingdom
|
-$7.46M |
| 5 |
Renaissance Technologies
New York
|
-$6.67M |
ENTA Hedge Fund Activity: Q1 2021 in Review
150 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q1 2021, worth a combined $957M — up 18% from $811M a quarter earlier.
Fund positioning in ENTA was balanced in Q1 2021: 15 funds opened new positions, 15 closed out, 54 added to existing stakes and 57 trimmed.
The largest buyer was Northern Trust, adding an estimated $20.3M. The largest seller was Invesco, cutting an estimated $11.9M.
- 150 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q1 2021, down from 151 in Q4 2020.
- Funds reported $957M of Enanta Pharmaceuticals stock for Q1 2021, up 18% quarter-over-quarter.
- 15 funds opened new Enanta Pharmaceuticals positions in Q1 2021 and 15 closed out, a net change of 0 holders.
- The largest Enanta Pharmaceuticals buyer in Q1 2021 was Northern Trust, an estimated $20.3M added.
- The largest Enanta Pharmaceuticals seller in Q1 2021 was Invesco, an estimated $11.9M sold.
Based on aggregated 13F filings for Q1 2021.